Form 4: Revelation Biosciences CFO Acquires Shares Through Restricted Stock Grant

Chester Stanley Zygmont III, CFO of Revelation Biosciences, acquired 15,048 shares of common stock at $3.87 per share on February 11, 2025, through a restricted stock grant.

Summary

• On February 11, 2025, Chester Stanley Zygmont III, the Chief Financial Officer of Revelation Biosciences, acquired 15,048 shares of common stock.
• The acquisition was made through a restricted stock grant under the 2021 Equity Incentive Plan.
• The price per share was $3.87.
• Following the transaction, Zygmont directly owns 28 shares and indirectly owns 15,076 shares through a trust and 13 shares through an LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by an insider, which doesn't inherently indicate positive or negative sentiment about the company's overall performance.

Positives

• The acquisition of shares by the CFO demonstrates confidence in the company's future prospects.
• The restricted stock grant aligns the CFO's interests with those of the shareholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• The stock acquisition by the CFO could have a slightly positive impact on shareholder confidence.

Key Dates

Keywords

Revelation Biosciences, REVB, CFO, Chester Stanley Zygmont III, Form 4, Stock Acquisition, Restricted Stock Grant, Equity Incentive Plan, Beneficial Ownership